& The AI Report
Good day, 360!
Here are some of our top movers today. And heads-up…
FOCUS LIST🔎
LIPO – Up over 100% in the pre-market after announcing FDA approval for expanded access program for LP-310 in Oral Lichen Planus
APPS – Up over 26% in pre after reporting better than expected earnings
IVVD – Up over 25% in pre, after trading this week up over 400% on positive results for alternative to COVID-19 vaccination
*sponsored by Morning Brew
The gold standard of business news
Morning Brew is transforming the way working professionals consume business news.
They skip the jargon and lengthy stories, and instead serve up the news impacting your life and career with a hint of wit and humor. This way, you’ll actually enjoy reading the news—and the information sticks.
Best part? Morning Brew’s newsletter is completely free. Sign up in just 10 seconds and if you realize that you prefer long, dense, and boring business news—you can always go back to it.
HOTLIST🔥
LIPO – Up over 100% in the pre-market after announcing FDA approval for expanded access program for LP-310 in Oral Lichen Planus
Lipella Pharmaceuticals Inc. (LIPO) is a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs.
In the pre-market this morning, the company announcedthat the U.S. Food and Drug Administration (FDA) has granted approval for an Expanded Access Program (EAP) for LP-310, an oral rinse formulation designed to treat oral lichen planus (OLP).
LP-310 is an innovative, localized therapy formulated to provide targeted relief for OLP patients while minimizing systemic exposure.
Oral lichen planus is a chronic inflammatory condition affecting the mucous membranes inside the mouth, often causing burning pain, white patches, swollen tissue and open sores. The condition impacts approximately 6 million Americans and currently has no FDA-approved therapies.
Expanded Access Programs allow patients who have unmet medical needs with serious or life-threatening conditions to access treatments outside of a clinical trial that are not yet approved by the FDA.
Shares of LIPO traded up over 100% in the pre-market in reaction to the news.
The first target for bulls is the pre-market high at $6.44. Beyond that, targets to the upside are $7, $7.50, $8 and $8.75.
Below $6.44, targets to the downside are $5.52, $5, $4.66, $4, $3.50 and then $3.
APPS – Up over 26% in pre after reporting better than expected earnings
Digital Turbine Inc. (APPS) through its subsidiaries, operates a mobile growth platform for advertisers, publishers, carriers, and device original equipment manufacturers (OEMs).
In the after-hours the company reported Q3 2025 financial results.
Highlights include:
Adjusted net income of $13.7 million, or $0.13 per share, on revenue of $134.6 million, down 6% year-over-year but up 13% sequentially
Adjusted EBITDA came in at $22 million, marking a 44% quarter-over-quarter increase despite a 13% annual decline.
Looking ahead, Digital Turbine raised its fiscal 2025 outlook, now expecting revenue between $485 million and $490 million (above the $477.05 million consensus) and adjusted EBITDA of $69 million to $71 million.
The company anticipates year-over-year revenue growth in the March quarter, with even stronger EBITDA gains.
Shares of APPS traded up over 26% in the pre-market in reaction to the news.
The first target for bulls is prior resistance at $3.40 and then the pre-market high at $3.49. Beyond that, $3.70, $4, $4.20. $4.62 and $5 come into play.
Below $3.40, targets to the downside are $3.12, $3, $2.93, $2.65 and then a gap fill at $2.54.
*sponsored by The AI Report
There’s a reason 400,000 professionals read this daily.
Join The AI Report, trusted by 400,000+ professionals at Google, Microsoft, and OpenAI. Get daily insights, tools, and strategies to master practical AI skills that drive results.
IVVD – Up over 25% in pre, after trading this week up over 400% on positive results for alternative to COVID-19 vaccination
Invivyd Inc. (IVVD) is a commercial-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
On Monday, the company announcedpositive data from its ongoing Phase 1/2 clinical trial of VYD2311, Invivyd’s novel monoclonal antibody (mAb) candidate designed to be a superior alternative to COVID-19 vaccination for the broad population as frontline protection in a convenient form, as well as to provide a novel, potent, long-acting option for the treatment of COVID-19.
Shares closed yesterday up over 400% for the week so far in reaction to the news.
Tuesday morning, HC Wainwright & Co. reiterated its Buy rating and maintained a $10 price target.
Shares of IVVD traded up another 25% in the pre-market above yesterday’s close, after trading up over 68% yesterday.
The $2.94 area acted as resistance in the pre-market and will be an important level to watch.
Above it, targets to the upside are $3 and then the pre-market high at $3.19. Beyond that, $3.40, $3.80, $4.20, $4.60 and $5 come into play.
Below $2.94, targets to the downside are $2.60, $2.35, $2.20, $2, $1.80, $1.60 and $1.40.
MARKET NEWS 📰
Don’t miss out on our MOBILE ALERTS! Some of these alerts have rocketed 🚀past the MOON 🌝. Text “RAGE” to 1-(888) 487-1534📲.
*Disclosure: By texting “RAGE” to 1-(888) 487-1534, you agree to receive promotional messages sent via an autodialer. You also agree to the terms of service and privacy policy. This agreement isn’t a condition of any purchase. Message frequency varies. Message and data rates may apply. Reply STOP to opt out; HELP for more information.
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
*Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
